CVS HEALTH Corp
CVS Health is a health care company headquartered in Woonsocket, Rhode Island, with four reportable segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. Its Aetna operations offer traditional, voluntary and consumer-directed health insurance and related services to individuals, employers and government-sponsored plans, including medical, pharmacy, dental and behavioral health coverage, Medicare products and Medicaid services. CVS Health also operates approximately 9,000 retail locations and more than 1,000 walk-in and primary care medical clinics. Through CVS Caremark, Health Services provides pharmacy benefit management, specialty and mail order pharmacy services, clinical and disease management, and health care in clinics, virtually and in the home. It also operates a group purchasing organization and works with pharmaceutical manufacturers on biosimilar products through Cordavis. The company serves employers, health plans, government programs, patients and other health benefit sponsors. It makes money from insurance products and services, pharmacy benefit management and related administrative services, pharmacy operations, and health care services.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
CVS Health plans to spin off its retail pharmacy business, including 9,000 stores and MinuteClinics, into a separate publicly traded company by 2028. The remaining entity will retain Aetna, CVS Caremark, and other healthcare units. Analysts note that the most impactful segments remain intact, potentially fueling congressional efforts to break up healthcare conglomerates.
142 companies reported earnings, with 86% beating EPS estimates and 78% showing Y/Y earnings growth. Notable performers include Apple (AAPL), Palantir (PLTR), AMD, Super Micro Computer (SMCI), Pfizer (PFE), Realty Income (O), Qualcomm (QCOM), Uber (UBER), McDonald's (MCD), and CVS Health (CVS).
CVS Health reported Q3 2026 earnings of $2.09 per share, beating estimates, with revenue at $108 billion. Despite this, its stock fell 12.5% on the day, while peers like Elevance Health rose. Operating income increased year-over-year to $3.57 billion. Management raised its 2026 EPS outlook and expects growth in 2027, but the Health Services segment faces challenges. CVS plans to split into two companies by mid-2028.
Over the past 7 days, AlphAI's AI scored 192 news stories mentioning CVS (CVS HEALTH Corp). Coverage has skewed bearish: 33 bullish, 94 neutral, and 65 bearish.
Recent CVS coverage spans corporate actions, earnings and financial news.
In the last 30 days, CVS insiders filed 1 SEC Form 4 transaction — 1 purchase ($2.0M) and no sales. The most active reporter was Shah Prem S, EVP and Group President, with 1 filing.
The spin‑off could unlock value by separating high‑growth pharmacy services from the insurance and PBM businesses, but leaves core insurance and specialty units together, creating uncertainty about future earnings and regulatory exposure.
Significant decline despite earnings beat and guidance raise.
The earnings beat and raised guidance were outweighed by concerns over the upcoming split, causing sell pressure.
Corporate split may unlock value for each unit.
The insider purchase suggests bullish sentiment and could support the stock price in the near term.
AlphAI scores every news story that mentions CVS with an AI model for sentiment and relevance, and aggregates insider trades from CVS HEALTH Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
CVS Health plans to spin off its retail pharmacy business, including 9,000 stores and MinuteClinics, into a separate publicly traded company by 2028. The remaining entity will retain Aetna, CVS Caremark, and other healthcare units. Analysts note that the most impactful segments remain intact, potentially fueling congressional efforts to break up healthcare conglomerates.
142 companies reported earnings, with 86% beating EPS estimates and 78% showing Y/Y earnings growth. Notable performers include Apple (AAPL), Palantir (PLTR), AMD, Super Micro Computer (SMCI), Pfizer (PFE), Realty Income (O), Qualcomm (QCOM), Uber (UBER), McDonald's (MCD), and CVS Health (CVS).
CVS Health reported Q3 2026 earnings of $2.09 per share, beating estimates, with revenue at $108 billion. Despite this, its stock fell 12.5% on the day, while peers like Elevance Health rose. Operating income increased year-over-year to $3.57 billion. Management raised its 2026 EPS outlook and expects growth in 2027, but the Health Services segment faces challenges. CVS plans to split into two companies by mid-2028.
U.S. stocks ended the week lower, with the S&P 500 down 2.7%, Nasdaq down 3.4%, and Dow down 0.9%. Tech stocks fell due to AI spending concerns and election results. Apple reported revenue of $114.5B, missing China expectations. AMD saw data center revenue nearly double. Palantir raised guidance. CVS plans a split, and Disney considers job cuts. Snap settled a social media addiction lawsuit. The week ahead focuses on the U.S. CPI report.
CVS EVP Prem Shah bought 23,855 shares for $2.0M at $83.89 on Nov 6, 2026, two days after a 12.5% stock drop due to a planned spin-off. Shah, who will lead the retail spin-off, increased his stake by 37%. Goldman Sachs lowered its price target to $115 from $120.
Shah Prem S (EVP and Group President) purchased 23,855 shares of CVS HEALTH Corp (CVS) at $83.90 ($2.00M total) on 2026-11-06.
CVS Health plans to split into two businesses, one for PBM and insurance, the other for retail pharmacies. The company says this will not immediately affect Tennessee patients, despite a new state law banning large chains from owning PBMs. CVS is suing to challenge the law's constitutionality, citing potential impacts on 1.5M+ pharmacy patients in Tennessee.
CVS Health (NYSE: CVS) shares fell 12% despite beating Q3 2026 earnings and revenue estimates, as the company announced a surprise plan to split into two entities in 2028. Management provided few details on the separation, including debt and dividend allocation, causing uncertainty. Analysts mostly maintain Buy ratings, but some have lowered price targets.
CVS Health plans to split into two companies: one for healthcare solutions, the other for retail pharmacy. Zipline raised $1.5B for medical drone delivery. Google will restrict AI tools for K-12 students unless schools opt-in. Multiple healthcare and biotech firms announced funding rounds.
Dr. Reddy's (RDY) secured Brazil approval for generic semaglutide and tentative FDA approval for an HIV prevention shot. Lupin (LUPIN.NS) and Sun Pharma (SUNPHARMA.NS) received FDA approvals for generic Firdapse and Ilumya. Agios (AGIO) and Ultragenyx (RARE) announced significant job cuts. CVS (CVS) plans to split into two publicly traded companies. Teva (TEVA) expanded its biosimilars portfolio through a deal with Samsung Bioepis.
